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ABSTRACT
Point-of-care clinical trials are randomized clinical trials designed to maximize prag-
matic design features. The goal is to integrate research into standard care such that the
burden of research is minimized for patient and physician, including recruitment, random-
ization and study visits. When possible, these studies employ Bayesian adaptive methods
and data collection through the medical record. Due to the passive and adaptive nature of
these trials, a number of unique challenges may arise over the course of a study.
In this dissertation, adaptive methodology for Bayesian time-to-event clinical trials is
developed and evaluated for studies with limited censoring. Use of a normal approxima-
tion to the study parameter likelihood is proposed for trials in which the likelihood is not
normally distributed and assessed with respect to frequentist type I and II errors. A pre-
viously developed method for choosing a normal prior distribution for analysis is applied
with modifications to allow for adaptive randomization. This method of prior selection in
conjunction with the normal parameter likelihood is used to estimate future data for the
purpose of prediction of study success. A previously published method for future event
estimation is modified to allow for adaptive randomization and inclusion of prior informa-
tion. Accuracy of this method is evaluated against final study numbers under a range of
study designs and parameter likelihood assumptions. With these future estimates, we pre-
dict study conclusions by calculating predicted probabilities of study outcome and compare
them to actual study conclusions. Reliability of this method is evaluated considering prior
distribution choice, study design, and use of an incorrect likelihood for analysis.
vi
The normal approximation to non-normally distributed data performs well here and
is reliable when the underlying likelihood is known. The choice of analytic prior distribu-
tion agrees with previously published results when equal allocation is forced, but changes
depending on the severity of adaptive allocation. Performance of event estimation and pre-
diction vary, but can provide reliable estimates after only 25 subjects have been observed.
Analysis and prediction can reliably be carried out in point-of-care studies when care is
taken to ensure assumptions are reasonable.
vii
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1Chapter 1
Introduction
1.1 Background
1.1.1 Pragmatic Clinical Trials
Randomized clinical trials have become a standard in clinical research geared toward de-
termining the efficacy and safety of interventions. These trials can range in nature from
explanatory to pragmatic, where explanatory trials aim to quantify and compare efficacy
under optimal conditions and pragmatic trials evaluate effectiveness of interventions un-
der ”realistic” conditions. [1] While explanatory trials are important for determining how
much better one treatment is than another, pragmatic trials are desirable when the goal is
to help healthcare workers make more informed clinical decisions. [2]
When we wish to compare interventions that are already approved and in regular use,
we are less interested in understanding why and how they work. We are more concerned
with gaining information that will allow clinicians to make a decision about which of the
treatments is best for their patients. When this is the case, a pragmatic trial may be more
appropriate than an explanatory trial. [3, 4] Pragmatic trials increase generalizability that
an explanatory trial may lack due to the very specific patient population that is targeted in
order to obtain estimates of effectiveness. Unfortunately, as in explanatory trials, pragmatic
clinical trials are involved and expensive due to the need for dedicated study staff to recruit,
randomize, treat and monitor patients. As such, a system in which the processes of a trial
can be embedded into normal healthcare procedures would reduce the fiscal and personnel
burden. Vickers and Scardino suggest a ”clinically-integrated randomized trial” in which
2the experience for randomized and non-randomized patients is virtually the same. [5]
Enrolled patients are burdened with as few study-specific encounters as possible.
1.1.2 Point-of-Care Clinical Trials
Point-of-care (POC) clinical trials are randomized clinical trials designed to maximize
pragmatic design features, while reducing the need for large budgets and dedicated study
personnel. [6] The goal is to integrate research into standard healthcare practices such that
the burden of research is minimized for both patient and health care practitioner. This
includes recruitment and randomization, to the extent possible. Additionally, we desire
for patients to be treated with the best treatment available. Such studies are best suited
to trials in which the comparison(s) of interest is between interventions that are already
approved and commonly used in practice. Ideally, outcomes may be ascertained from
electronic medical records without the need for additional follow-up visits. [7] This type
of study design promotes more immediate adoption of study results into clinical practice,
and thus, encouragement to become a ’learning healthcare system’.
1.1.3 Adaptive Randomization
Adaptive randomization is a method to maximize the number of patients treated with the
superior treatment and is appropriate in this setting in which the goal is to mimic clinical
practice. This is done by updating the randomization probability at interim analyses to
favor the better performing intervention based on data collected to that point in time.
Many adaptive methods have been proposed or reported in the literature. Cheng and Shen
propose randomization probability based upon a loss function weighted by the costs of pa-
tient care and the costs of choosing the wrong intervention. [8] A randomization allocation
ratio as a function of weighted parameter estimates was suggested by Karrison, Huo and
Chappell. [9] Thall and Wathen reviewed characteristics of designs using a randomization
probability that is a function of the posterior probability of success, the same employed in
Fiore, et al’s POC trial. [10]
3Adaptive randomization allows patients to be treated with the best intervention based
on the most current available data. This is considered more ethical because as we know
more about the treatments we can make more informed decisions about what is best for pa-
tients. [11] It has been successfully used in a number of research areas, including leukemia
studies [12, 13], depression [14], and cancer [15]. Because POC studies are comparing treat-
ments that have been previously proven effective and safe, the question of interest is not
whether the treatments work but which treatment is best for patients in real life situations
in a population that is broadly defined. The main advantages of adaptive randomization
are that we treat patients with the intervention believed to be best at any given time and
less time may lapse before making a decision about treatments because we are continually
increasing the percentage of participants treated with the better treatment.
However, most trial theory assumes that treatment groups are equally allocated, which
is unlikely in an adaptive scenario where treatments are quite different. Additionally, sta-
tistical power is optimized when treatment groups are the same size. Fiore, et al envision
POC studies as largely unblinded, which increases the potential for cross-contamination of
treatments, and thus, reduced effect size between the treatment arms. Therefore, point-of-
care clinical trials may be particularly suited to adaptive randomization since the treatment
group sizes are not expected to become extremely skewed. Furthermore, adaptive random-
ization encourages the ’learning healthcare system’ environment by immediately affecting
treatment practice with study data.
1.1.4 The Normal Distribution Framework for POC Trials
As the study progresses and the treatment groups become increasingly unbalanced, calcu-
lation of posterior and randomization probabilities becomes complicated. Many quantities
of interest are not calculable in closed form and require involved simulations. The use of
the normal distribution facilitates a range of decision analyses, such as the computation
of predictive probabilities, that may otherwise be very complex. Calculations are much
simpler when working within the normal distribution framework. The normal distribution
4has many desirable properties for which there is already a great breadth of knowledge. A
normal approximation to the data likelihood would facilitate use of conjugate normal priors
for design and analysis of the trial, thereby providing a normal approximation for the whole
trial design. Posterior calculations within the normal construct are straightforward and
available in closed-form. While some other data likelihoods also have potential conjugate
priors, this conjugacy may be lost if another distribution is chosen to model the data.
Clearly, not all data follows a normal distribution. However, there is an extensive
literature on possible transformations that lead to a normal likelihood for parameters.
[16, 17, 18, 19, 20, 21, 22] We may then be able to apply a normal approximation to data
that has undergone a transformation to better fit a normal distribution. With this toolkit,
a much larger number of analyses may be carried out under the normal distribution free
of complicated simulations.
1.1.5 Predicting Study Outcome - Predictive Power
One potentially complicated process in clinical trials of all types is prediction of the study
outcome. Prediction is needed in clinical trials when we want to have an educated guess
about what will happen at the end of the study. This can be done with primary endpoint
data, surrogate endpoints, or auxillary data. Given the cost and time commitments of
clinical trials it is desirable to be able to determine whether it is likely that a trial will
produce a positive result prior to trial completion. [23] This is done on partial trial data
which is used to develop our best guess as to whether or not the null hypothesis will be
rejected at the end of the study.
In frequentist clinical trials this type of decision is carried out by means of calculating
conditional power. [24] Conditional power is the probability that the study will end with
a significant result, given what has already been observed in the study and an assumption
about the treatment effect to be seen in future data. In the Bayesian context, however,
prediction of trial success is achieved by assessing predictive power. Predictive power is
the probability that the study will end with a significant result, given observed data and
5prior data about the study outcome. Predictive power has the potential to provide a more
thorough picture about the future of the study. [25]
Being able to make a reliable determination about conclusions to be drawn at study
end has the potential to save a great deal of time and money if a study is unlikely to
be successful. As such, a futility assessment may be of particular interest to determine
the likelihood of a study achieving its goals. [26] Given the number of clinical trials that
ultimately fail to support their hypotheses, the potential savings in staff and financial
resources are vast. However, great care should be taken to minimize the likelihood that a
study is inappropriately stopped early. [27] Futility assessment based on predictive power
has the benefit of not being restricted to a single effect size, and may thus be a safer
approach in ensuring appropriate stopping rules. [28]
1.2 Motivating Problem
We consider a case comparing two approved methods for administering insulin to patients
hospitalized for hyperglycemia. [6] The outcome of interest is median length of stay (LOS)
in the hospital. Interim analyses with predetermined stopping rules are planned a priori.
Patients are equally allocated at the beginning of the study, and as the study progresses,
more patients are randomized to the better performing treatment (i.e. the treatment
associated with the shorter hospital stay) until the planned maximum number of patients
are randomized or the study ends for efficacy.
Patients are randomized in K batches and the randomization proportion is updated at
each interim analysis. The proportion randomized to group A,
piA =
(pA)
η
(pA)η + (1− pA)η (1.1)
is a function of the posterior probability of success, pA = P (group A superior to group
B | data), which is updated at each interim analysis, and a calibration parameter, η > 0,
designed to further refine the proportions randomized to each treatment group. [10] When
6η = 0 equal allocation to treatment groups is maintained. When η = 1 subjects are random-
ized to treatment group A with probability pA and to treatment group B with probability
1 − pA. Values of η less than 1 lead to patients being randomized to treatment group A
with probability between 0.5 and pA. Similarly, η values greater than 1 lead to patients
are randomized to treatment group A with probability greater than pA). The posterior
probability of superiority is a function of both the likelihood and the prior distribution,
specified a priori.
Figure 1.1 presents the flow of the adaptive design. Patients are allocated equally at
the beginning of the study and enrolled in equal-sized batches thereafter. After each batch
of patients is enrolled, the randomization proportion is updated under the formulation
above (1.1) and the next batch of incoming patients are enrolled under the newly updated
randomization proportion. At each interim analysis pA is compared to a predetermined
stopping bound, b. If pA surpasses this stopping bound, the null hypothesis is rejected and
the study is stopped.
The concept design proposed by Fiore, et al proposes to enroll a maximum of 3,000
patients enrolled in batches of 200 with no analysis after the first batch. Hospital LOS is
assumed to be exponentially distributed with median λ and is administratively censored
at 30 days. The median is assumed to be distributed inverse gamma with shape parameter
α = 100. Therefore, the posterior distribution of median LOS also follows an inverse
gamma distribution. At each interim analysis, pA is compared to b = 0.99. The null
hypothesis that the median LOS is the same in each treatment group will be rejected if
pA > b or pA < 1 − b. The randomization probability is updated and calibrated with
η = 0.5.
1.3 Goals of the Dissertation
This dissertation explores the the use of a normal approximation to non-normal likeli-
hood, prior and posterior distributions for use in a number of commonly executed tasks
7Figure 1.1: Flow of an Adaptive Clinical Trial for Evaluating Insulin Administration Meth-
ods
in adaptive clinical trials. In Chapter 2, we describe the methodology for establishing an
approximate normal likelihood and prior distribution and evaluate its performance with re-
spect to our motivating problem. In particular, we focus on time-to-event outcomes, which
are known for their skewed distributions. In Chapter 3 we adopt a method for analysis
of a Bayesian clinical trial with normally distributed outcomes to studies with outcomes
approximated by a normal posterior distribution. We also evaluate the effect of adaptive
randomization on this method. We discuss how this approach is used by application to our
motivating problem.
Chapters 4 and 5 address the difficulty of prediction in adaptive clinical trials. In
Chapter 4, we discuss the need for estimation of future events and discuss the potential
difficulties in adaptive trials. Reliability of this estimation method is discussed and sum-
8marized. We also evaluate accuracy of this estimation method under a wide range of study
designs and underlying likelihoods. In Chapter 5, estimation methods from chapter 4 are
applied in order to predict conclusions at study end by calculating predictive power. Ex-
tensive simulations are used to explain how study parameters and underlying likelihoods
effect the relationship between observed and predicted trial outcomes.
We conclude, in Chapter 6, by summarizing the main conclusions, examining the limi-
tations of the methodologies proposed, and suggesting areas for future research.
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Normal Approximation
2.1 Motivation
Since the normal distribution facilitates a number of decision analyses, this dissertation
proposes use of a normal likelihood (or approximation with a normal likelihood, when the
likelihood of the study parameter of interest is not normal) in conjunction with a normal
conjugate prior for analysis in adaptive clinical trials. In many cases, a transformation of
the parameter under study might be needed to achieve approximate normality. [22]
In trials in which the comparison of interest is a continuous difference between treatment
groups, it is straightforward to consider the distribution of the difference between those
groups. Assuming that the sampling distribution of the parameter of interest is normally
distributed within each treatment group, the difference between treatment groups is also
normal. The posterior probability that A is superior to B, pA, assuming a conjugate normal
prior, can be obtained analytically from a normal posterior distribution,
P (A > B|Data) = P (A−B > 0|Data)
= P (θA−B > 0|Data)
= P
(
θA−B − µθA−B |Data
σθA−B |Data
>
−µθA−B |Data
σθA−B |Data
)
≈ P
(
Z >
−µθA−B |Data
σθA−B |Data
)
= 1− Φ
(
−µθA−B |Data
σθA−B |Data
)
10
We define θA−B as the true difference in means between groups A and B, µθA−B |Data as
the posterior mean difference between A and B, and σ2θA−B |Data as the posterior variance
of the mean difference between A and B. This critical probability calculation is then easily
calculable in closed form.
2.2 Method
While these calculations are straightforward for normally distributed posterior distribu-
tions, this may not be the case for other likelihoods and prior distributions. In this case, it
may be necessary to reparameterize the data likelihood to allow for a normal posterior dis-
tribution. There are a number of commonly used transformations that may be appropriate
for modifying the likelihood, with the log and square root functions being among the most
common. There is a vast theoretical literature to support transformations to normality.
The delta method can be applied to transform the study parameter when the sample
size is appropriately large. The likelihood should be known in order to apply this method.
We also need to know the maximum likelihood estimate for the parameter of interest.
The delta method then allows us to estimate the variance of the transformed maximum
likelihood estimate for use in the likelihood.
To further facilitate calculations, a normal prior distribution, of the form θ ∼ N
(
δ,σ
2
/n0
)
,
is also desirable. Approximating the prior distribution with a normal distribution can be
achieved using the method of moments. By using the moments of the exact prior distribu-
tion, we can create a normal prior distribution that contributes the same amount of weight
to the analysis as the exact prior. We apply this method by integrating the true prior
distribution to find the expectation and variance of the transformed parameter.
The normal likelihood in conjunction with the normal conjugate prior gives us a normal
posterior distribution for analysis of the form
θ|Y ∼ N
(
my + n0δ
m+ n0
,
σ2
m+ n0
)
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where m + n0 is the effective study sample size for a treatment group. The mean of the
posterior distribution is a weighted average of the likelihood and prior distribution and the
variance is the standard error over the entire effective study sample size.
2.3 Motivating Problem
2.3.1 Exact Model
We assume that hospital length of stay for each treatment group follows an exponential
distribution parameterized by the median, λ. The likelihood of interest for each treatment
group is
L (λ|T, δ) =
[
log(2)
λ
]∑ δi
exp
(
− log(2)
λ
∑
ti
)
where ti = min(ci, si) is the observed event time for each patient. Here ci is the cen-
soring time and si is the time until each patient experiences an event. Additionally,
δi = I (si < ci) is a censoring indicator and follows a Bernoulli distribution with prob-
ability ρi = P (si < ci). In this study we assume a fixed censoring time, independent of the
distribution of events, leaving only the censoring indicator and length of stay as random
quantities.
The conjugate prior distribution for λ is an inverse gamma prior distribution of the
form
λ ∼ IG (α, β)
with mean βα−1 and variance
β2
(α−1)2(α−2) .
The posterior distribution for λ conditional on the observed data T then follows an
inverse gamma distribution of the form
λ|Data ∼ IG
(
α+
∑
δi, β + log(2)
∑
ti
)
Conclusions about the differences in length of hospital stay are based on the posterior
probability that one treatment is superior to the other.
12
2.3.2 Transformation
Since the normal distribution provides a simpler context in which to calculate probabilities
concerning the outcome, we propose a normal approximation for the log of the median
length of stay in conjunction with a normal conjugate prior. Since the natural log is a
monotone function, inferences about log of the median will be analogous to inferences
about the median itself.
The graphs in Figure 2.1 represent the exponential likelihood as a function of the median
(left) and the exponential likelihood as a function of the natural log of the median (right).
The likelihood as a function of the median is extremely right skewed while the likelihood
as a function of the natural log of the median is more similar to a normal curve. This
indicates that the natural log may be an appropriate transformation for this likelihood and
prior. The normal likelihood and prior will be about the parameter log (λ).
Figure 2.1: Likelihood of Median and log(Median)
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2.3.3 Approximate Model
The delta method is employed to find the form of the likelihood as a function of log (λ).
The maximum likelihood estimate for λ, λˆ, is
log (2)
∑
ti∑
δi
and an estimate of the variance of λˆ using Fisher Information is
V ar
(
λˆ
)
=
λ2∑
δi
Thus, a candidate normal likelihood as a function of log (λ) would have mean
E (log (λ)) = log
(
λˆ
)
= log
(
log (2)
∑
ti∑
δi
)
and variance
Var (log (λ)) =
(
d log (λ)
dλ
)2
×Var
(
λˆ
)
=
1∑
δi
The variance takes a form similar to that of the sample mean, with population variance
in the numerator (equal to one in this example) and ’sample size’ in the denominator. In
this example in which we have a time-to-event outcome, the sample size for the likelihood
is the number of observed events.
One potential difficulty could occur if there are zero observed events in a treatment
group. This would cause the denominator in both the mean and variance estimates of
the normal approximation to the likelihood to be zero, leaving the likelihood parameters
unestimable. To prevent this, we add 0.5 to the total number of events to ensure non-zero
14
denominators. As data acccrues, this additional 0.5 will have a decreasing and eventually
negligible effect on the parameter estimates.
The series of plots (Figure 2.2) of the original exponential likelihood in terms of log (λ)
and the normal approximation to the likelihood show that the two likelihoods are nearly in-
distinguishable for samples sizes of 50, 100, 200, 500, 1,000, and 10,000. Not unexpectedly,
the normal approximation improves with increased sample size. In general, the normal
approximation and the exponential likelihood for log (λ) are very similar, particularly for
large sample sizes.
Figure 2.2: Exact Distribution of log(Median) vs. Normal Approximation of log(Median)
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To take advantage of the conjugacy of the normal distribution, we assign a normal prior
distributions to the log of the median length of stay in each treatment group of the form
log (λ) ∼ N
(
µ, 1n0
)
where µ is the mean and n0 is the sample size of the prior distribution.
With a normal likelihood and a normal prior distribution, the resulting posterior dis-
tribution for log (λ) is also normal with distribution
log (λ) |Data ∼ N
∑ δi × log
(
λˆ
)
+ n0µ∑
δi + n0
,
1∑
δi + n0

where
∑
δi + n0 is the effective sample size for a given treatment group. We need to
ensure that the priors to the approximate and exact models provide the same amount of
information to the posterior distribution for log (λ). To do this, we use the method of
moments to find the mean and variance of log (λ) when λ follows the inverse gamma prior
above.
To find the mean and variance, we let X = 1λ , where
1
λ follows a gamma distribution
with parameters α and 1β , and Y = βX. The expectation of log (X) is
E [log (X)] = E
[
log
(
Y
β
)]
= E[log (Y )]− log (β)
=
∫ ∞
0
log (y) yα−1exp (−y) dy − log (β)
= ψ (α)− log (β)
where ψ (α) is the digamma function such that ψ (α) = d log Γ (α) /dα. [29] Since this is
the mean of log
(
1
λ
)
we negate this quantity to find the mean of log (λ) by
E
[
log
(
1
λ
)]
= E [− log (λ)] = −E [log (λ)]
To find the variance, we need the second moment of log (X). The second moment is
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calculated as
E
[
log2 (Y )
]
= E
[
log2 (Y )− 2 log (β) log (Y ) + log2 (β)]
=
∫ ∞
0
log2 (y) yα−1exp (−y) dy − 2 log (β)E [log (Y )] + log2 (β)
= ψ2 (α) + ζ (2, α− 1)− 2 log (β)ψ (α) + log2 (β)
= (ψ (α)− log (β))2 + ζ (2, α− 1)
where ζ (2, α− 1) is the zeta function such that ζ (2, α− 1) = ∑∞i=0 (i+ (α− 1))−2. [29]
Thus the variance of log (X) and subsequently log (λ), is
V ar [log (X)] = E
[
log2 (X)
]− E2 [log (X)]
= ζ (2, α− 1)
Therefore, the sample size of the prior distribution is n0 =
1
ζ(2,α−1) and the form of the
prior distribution is
log (λ) ∼ N
(
log (β)− ψ (α) , 11
ζ(2,α−1)
)
Thus, the normal posterior distribution for log (λ) is
log (λ) |data ∼ N
∑ δi × log
(
λˆ
)
+ µ/ζ (2, α− 1)∑
δi + 1/ζ (2, α− 1) ,
1∑
δi + 1/ζ (2, α− 1)

The effective sample size of the study is n0 =
∑
δi + 1/ζ (2, α− 1), a combination of the
number of events observed in the data and the weight of the prior distribution in units of
events. The mean of the normal posterior distribution is an average of the mean of the
likelihood and prior distributions weighted by their respective sample sizes.
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2.3.4 Exact vs. Approximate Models
Since we are proposing use of a normal approximation for analysis of a study with an
inverse gamma posterior, we need to ensure that the results and conclusions under the
normal approximation are consistent with those under the inverse gamma distribution.
Figure 2.2 indicates that these two distributions are very similar, but we seek to mea-
sure how consistent they really are with respect to decisions about the treatment groups.
Of particular interest is how often the normal approximation leads to study conclusions
contrary to conclusions reached under the inverse gamma posterior.
We examined 2,100 scenarios under the null hypothesis and 20% difference in treatment
groups. The shape parameter of the inverse gamma prior (i.e. the weight of the prior
distribution) varied from 2.001 to 100, η ranged from 0 to 2, and the rejection bound b
ranged from 0.95 to 0.999. We considered studies with sample sizes from 1,000 to 5,000
with pack sizes of 100 to 500. Enrollment followed a Poisson process with a rate of 5
enrollees per day. We carried out 10,000 simulations of each scenario and calculated the
proportion of simulations that did and did not reject the null hypothesis by the end of the
study. These proportions were used calculate type I and II errors under each scenario. This
was done under the exact inverse gamma posterior and using the normal approximation
to the inverse gamma posterior. For each scenario, we calculated the type I and type II
errors across the 10,000 simulations. That is, there was one value for each type of error for
each scenario for both normal and inverse gamma posteriors.
To evaluate the performance of the normal approximation we compare frequentist type I
and type II errors under the inverse gamma posterior and the normal posterior distributions
(Figure 2.3). Type I error under the exact and approximate models is very similar. Power
under the two models is also similar, though there is more variation between the models
than in type I error. Generally, the power under the exact inverse gamma posterior is higher
than that of the normal posterior. However, the average difference in power between the
two methods is only 0.13%.
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Figure 2.3: Frequentist Type I Error and Power Under Inverse Gamma and Normal Pos-
teriors
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However, the study designs with desirable power (80% or greater) under the exact model
have more similar power under the approximate model than studies with higher type II
error (2.4). While the exact model has generally higher power than the approximate model,
the average difference in power between the two methods is only 0.07%.
2.3.5 Analyzing the Difference between Treatment Groups
When we know the form of the normal posterior distribution for each treatment group,
finding the distribution of the difference between the treatment groups is trivial. The
distribution of the difference has mean
log (λA)− log (λB)
and variance
1∑
δiA
+
1∑
δiB
19
Figure 2.4: Studies with Frequentist Type I Error ≤ 5% and Power ≥ 80% Under Inverse
Gamma and Normal Posteriors
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A conjugate prior for the difference is a normal distribution with a mean of a specified
difference between treatment groups and variance
1
n0A
+
1
n0B
Under the gamma distribution, α can be roughly interpreted as the sample size of the
prior distribution. We can solve n0 = 1/ζ (2, α− 1) numerically for α to establish values
of n0 and α for which the inverse gamma and normal distributions will be approximately
equivalent. These values are given in Table 2.1. The values for n0 and α are roughly equal,
particularly for large samples. The parameters differ most for small values of n0 for which
the weight of the prior distribution would be very small, and thus when the differences will
have the least effect.
When considering the difference between the treatments, we no longer need to make
the transformation between the inverse gamma and normal distributions. Knowing the
equivalent values for n0 and α is enough to construct a normal prior distribution.
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Table 2.1: Equivalent values of α and n0
α n0
3.46 2
11.484 10
21.469 20
51.390 50
101.253 100
151.44 150
250.993 250
500.808 500
750.724 750
900.692 900
2.3.6 Discussion
The first step in establishing a normal approximation to a non-normal posterior distribution
is to determine if there is a transformation of the parameter of interest that leads to a good
normal approximation. In our example the natural log works well, but there are many such
transformations available. Once a suitable transformation is chosen, the delta method can
be applied to find the form of the normal likelihood approximation.
Additionally, it may be helpful to parameterize the data likelihood in an unconventional
way. In our example, we parameterize distribution of hospital length of stay by the median
rather than the rate of the exponential distribution. This may also aid in finding an
adequate approximation.
To take advantage of the conjugacy of the normal distribution, a normal prior distri-
bution can be chosen to compliment the normal likelihood. If non-normal prior is known,
the method of moments can be used to determine a normal prior that contributes the same
weight as the original prior. Otherwise, the parameters of the normal prior can be chosen
such that the study maintains desirable operating characteristics.
The normal approximation applied to the likelihood, prior and resulting normal poste-
rior distributions in our motivating problem developed in this chapter will be used through-
out the remainder of the dissertation.
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Chapter 3
Prior Specification
3.1 Motivation
The choices for a prior are virtually unlimited and narrowing the options can be challeng-
ing and time-consuming. Additionally, choosing appropriate prior parameters can require
a complicated, iterative simulation process to ensure that the choice of prior maintains
desired operating characteristics. We seek a method for choosing a prior distribution that
is relatively simple (i.e. simulation-free) that can control the possibility of erroneous early
stopping, thus placing bounds on type I error.
When a normal likelihood is available, a normal prior distribution is often desirable.
Choosing a prior distribution for analysis can be a complicated, subjective process, but it is
possible to apply the method of moments to find an equivalent normal prior when an exact
prior distribution is known. Further, when an exact distribution is not known or there
isn’t a clear conjugate prior, it may be impossible to find an equivalent normal prior. It
may be more efficient and desirable to bypass the process of translating a non-normal prior
distribution to its normal approximation. For normally distributed parameter likelihoods,
methods exist for selecting reasonable analytic normal prior distributions. However, these
methods for simplified prior assignment assume a balanced design. Therefore, in this
chapter, we propose a method for choosing a normal prior distribution for clinical trials
with adaptive randomization allowing unbalanced sample size and a normal parameter
likelihood or a normal approximation to the parameter likelihood.
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3.2 Grossman’s Method
Grossman, et al proposed a novel method for determining a normal prior distribution in
Bayesian sequential, equally-allocated clinical trials with a normally distributed outcome
that controls for early stopping and maintains desirable frequentist operating character-
istics. [30] This choice is dependent on the number of planned interim analyses and the
desired type I error.
The posterior distribution incorporates information from both the parameter likelihood
and the prior distribution. While the study sample size is reflected in the parameter
likelihood, the prior distribution also contributes weight to the analysis in a sample size
of its own. The effective sample size of the trial is a combination of subjects observed in
the data and those contributed by the prior distribution. At each analysis, the effective
sample size suggested by Grossman at stage k is
ek =
e× k
K
+ f × e
where k is the number of the current analysis, K is the total number of analyses to be
conducted, e represents the total number of subjects to be enrolled, and f is the handicap.
That is, f is a proportion applied to the total number of patients, and f × e is the sample
size of the normal prior distribution. As the study progresses, the observed data will
overcome the information contributed by the prior distribution.
The observed mean difference statistics for each group of subjects enrolled has distri-
bution
Yk|θ ∼ N
(
θ,
σ2K
e× k
)
For a prior distribution, Grossman, et al propose a normal distribution with a mean
treatment difference of zero and variance σ
2
f×e .
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Thus, the form of the resulting normal posterior distribution is
θj |Ykj ∼ N
(
e×k
K × ykj + f × e× δj
ekj
,
σ2
ekj
)
At each analysis the usual standardized Z test statistic is calculated based only on data
observed to that point in the study. The test statistic is then compared to the expanded
critical region
±Z1−α
2
√
k + fK
k
The handicap, f , is chosen such that the study design adheres to desired frequentist operat-
ing characteristics. This, in turn, designates the information that the prior distribution will
contribute to the posterior distribution used in analysis. The application of this handicap
has an effect not unlike that of an O’Brien-Fleming or Pocock group sequential rejection
bound. [31, 32] It is a very simple method for choosing the prior distribution weight that
does not involve complicated trial simulations or extensive calculus. We aim to apply
Grossman’s method for choosing a normal prior when a normal approximation is used in
study designs with adaptive randomization.
3.2.1 Non-normal Data
Grossman’s method assumes that the study parameter of interest is normally distributed,
but this may not always be the case, as in time-to-event analyses. In the event that the
data are not normally distributed, we propose a normal approximation to the parameter
of interest followed by application of Grossman’s method. Given that this approximation
works, the prior is chosen such that the study design adheres to frequentist standards of
type I error. This is done by application of an appropriate handicap. Grossman, et al
provide a table of optimal handicaps for use in balanced non-adaptive randomized clinical
trials. Handicaps are given for studies with experimentwise type I error of 0.01 and 0.05.
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3.3 Motivating Problem
We apply the normal approximation for the difference in median survival developed in
Chapter 2. The use of a normal approximation on time-to-event data uses the number of
events for analyses rather than number of patients. Due to the adaptive nature of POC,
the number of events observed at a particular interim analysis will depend on the number
of events observed at the previous interim analysis. In order to not introduce any prior
assumed difference between treatment groups, per Grossman’s method, we assume that the
number of events experienced in each treatment group will be equal. Therefore, the number
of events expected at the end of the study will be approximately e = P (S < C)×N where
S is a subject’s length of hospital stay, C is a subject’s censoring time, and N is the total
number of patients to be enrolled when the study does not stop early. This probability is
calculated as the exponential cumulative distribution function with rate log (2) /λ.
Unlike the original POC design, the decision to reject the null hypothesis is based on a
test statistic compared to critical value rather than a probability of superiority compared
to probability bound. Randomization allocation probabilities are still updated via the
mechanism described, but the posterior probability of treatment superiority is no longer
used directly in analysis.
3.3.1 Handicaps for Adaptive Designs
In addition to application of the normal approximation, POC differs from the approach
proposed by Grossman in that treatment groups can grow increasingly more unbalanced
in size over the course of the study. The extent of the imbalance is controlled by η. When
η is zero, the randomization proportions are forced to be equal. This scenario is equivalent
to the approach proposed by Grossman. As η increases, the potential imbalance of the
treatment groups increases. We provide handicaps with use of the normal approximation
under a range of η values.
Tables 3.1 and 3.2 provide values for f that result in fixed type I error for α = 0.05 and
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0.01 for studies with up to 10 analyses. Handicaps calculated by Grossman are presented
along with handicap values in adaptive designs with randomization calibrations of 0, 0.5,
1, and 2. These results were obtained from computer simulation of 100,000 trials.
Table 3.1: Handicaps which fix type I error at 5 percent (using α = 0.05)
Number of Analyses Grossman η = 0 η = 0.5 η = 1 η = 2
1 0 0 0 0 0
2 0.16 0.17 0.16 0.16 0.15
3 0.22 0.22 0.22 0.21 0.19
4 0.25 0.25 0.24 0.23 0.20
5 0.27 0.27 0.26 0.25 0.21
6 0.29 0.29 0.27 0.27 0.22
7 0.30 0.31 0.29 0.28 0.23
8 0.32 0.32 0.31 0.29 0.24
9 0.33 0.33 0.31 0.30 0.24
10 0.33 0.33 0.31 0.30 0.24
Table 3.2: Handicaps which fix type I error at 1 percent (using α = 0.01)
Number of Analyses Grossman η = 0 η = 0.5 η = 1 η = 2
1 0 0 0 0 0
2 0.11 0.11 0.11 0.10 0.08
3 0.15 0.14 0.13 0.12 0.10
4 0.17 0.17 0.15 0.14 0.10
5 0.18 0.18 0.17 0.15 0.10
6 0.20 0.20 0.17 0.15 0.11
7 0.21 0.21 0.18 0.16 0.11
8 0.22 0.22 0.19 0.16 0.11
9 0.22 0.22 0.20 0.17 0.11
10 0.23 0.23 0.20 0.17 0.11
Under η = 0, when equal randomization to the treatment groups is maintained, Gross-
man’s handicaps are recovered. For η > 0, handicap values are less than or equal to those
established by Grossman. The larger the potential randomization skew, the smaller the
handicap values become.
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3.3.2 Discussion
Assuming use of the normal approximation, the handicap is another method to not only
choose a prior distribution, but to also control for multiple testing. The handicap assists
in determining the ’sample size’ to be contributed by the normal prior distribution. The
stopping boundary changes as the study progresses giving more weight to the observed
data. Thus, the weight of the prior distribution in the beginning of the study makes early
rejection more difficult. Early data needs to be extremely convincing in order to overcome
the skepticism contributed by the prior.
The handicaps established in this trial design with normal approximation and forced
balanced randomization are the same as those established by Grossman. This is not un-
expected given prior work indicating that very little information is lost by using the nor-
mal approximation rather than the exact model. Further, this indicates that it may be
acceptable to use a normal approximation to the data combined with Grossman’s prior
specification method when the study plans for balanced randomization.
While our handicaps for a balanced study design match those set forth by Grossman,
studies with skewed randomization tend to have smaller handicaps than those of a balanced
design. This is a product of the inverse relationship between handicap and variance of the
posterior distribution. For studies with early large differences between treatment groups,
the effect of large η on the number of patients randomized to each group will be magnified.
Application of a smaller handicap in these scenarios increases the variance of the posterior
distribution and therefore reduces the posterior probability of superiority. A small handicap
acts as a counterbalance to the large observed difference in treatment groups by attenuating
the posterior probability. This in turn forces more balanced randomization than would be
seen with a larger handicap because the probability being skewed by the randomization
calibration is closer to 0.5. As a result, early stopping is more difficult due to a decreased
probability of success.
The handicap changes very slowly for trials with more than four analyses, regardless of
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η. While the number of analyses for a trial should be decided in advance, the slow change
in the handicap above four analyses indicates robustness to the a posteriori addition of
analyses. Little information will be lost with respect to type I error in the case that a
study includes additional analyses that were not originally planned. In clinical trials the
ad hoc addition of interim analyses is not uncommon, so the handicap’s robustness to this
is a desirable property.
While the described prior specification method maintains type I error at pre-specified
levels, no work has yet been done to investigate power and optimal sample size in this
type of trial design. The previously described normal approximation facilitates power and
sample size calculations that are straightforward and familiar. Using a handicap to assign a
prior distribution in conjunction with the normal approximation of the likelihood simplifies
the calculations for power and sample size to widely used familiar formulas.
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Chapter 4
Estimating the Number of Future Events
4.1 Motivation
Estimates of future event numbers in a clinical trial can be used for many purposes in-
cluding prediction of study success and timing of data safety and monitoring meetings and
interim analyses. In order to ensure accurate and reasonable predictions, we need accurate
and reasonable estimates for the future data that is used as an input. For practical reasons,
future data is assumed to follow the same distribution as data that has already been ob-
served. When considering a time-to-event outcome, we need estimates of both the number
of events that will occur as well the additional time that each future subject will contribute.
However, in the case of the normal approximation to the exact underlying likelihood, we
need only an estimate of the number of events that will occur during the remainder of the
study. Due to the reliability and increased simplicity of future data inputs for prediction,
we propose continued use of the normal distribution, or approximation, where possible.
There are multiple ways to achieve future data estimates, including both simulations
and closed form solutions when reasonable distribution assumptions can be made about
the outcome of interest. We explore both approaches in this chapter and apply them to
our motivating problem.
4.2 Method
To estimate of the number of future events, n, at the current analysis we need to consider
patients that are already enrolled and patients that will enroll in the future. There may
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be patients currently enrolled that have not yet experienced an event. This could be due
to administrative censoring, patient withdrawal or dropout, or because the patient has not
yet been followed long enough for an event to be observed. An estimate of the number
of events occurring in patients already enrolled that will experience an event before study
end is needed.
We also need an estimate of the number of events that will occur in patients that have
not yet enrolled in the study. To do this, we assume a constant randomization probability
for all future enrollees. We also assume the same underlying distribution for future data
that has been observed in the collected data.
Bagiella and Heitjan propose a method for estimating the expected number of events
in each of these two scenarios. [33] Their formulas apply when censoring and survival
distributions are known or can be estimated. Suppose we are interested in the number
of events in a particular time interval, namely (t0, t). The number of events expected in
patients in treatment group j that have already enrolled in the study is estimated as
Qj (t0, t) =
Nj(t0)∑
i=1
Yji (t0)
[Fj (t− eji)− Fj (t0 − eji)]−
∫ t−eji
t0−eji Gj (u) fj (u) du
[1− Fj (t0 − eji)][1−Gj (t0 − eji)]
where Nj (t0) is the total number of patients in treatment group j enrolled at time t0, Yji is
an indicator for an event being observed prior to time t0, Fj is the cumulative distribution
function of the time-to-event outcome, Gj is the cumulative distribution function of the
censoring time, and eji is an individual’s enrollment time.
Likewise, the number of events expected to occur in patients in treatment group j that
have yet to enroll in the study is estimated as
Rj (t0, t) = ρν
−1
∫ t−t0
0
{∫ t−t0−u
0
fj (s) (1−Gj (s)) ds
}
du
where ρ is the subject enrollment rate and ν is the number of treatment groups being
studied.
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An important consideration when estimating future data is the rate at which patients
are enrolled in the study. In the above formula for Rj (t0, t), we specify ρ as the enrollment
rate. Unreasonable enrollment expectations can lead to poor estimates of time to data
monitoring meetings, interim analyses, and study end. Careful consideration should be
given to the value used. One simple suggestion is to use the observed patient accrual rate
up to the time of future data estimation. This value is constant, however, and may not
adequately reflect ongoing site start-up or other factors affecting the rate of enrollment. If
uniform patient accrual is not reasonable, there are a number of methods for making more
accurate enrollment projections. [34, 35, 36]
4.3 Motivating Problem
4.3.1 Number of Event Estimates for POC
To estimate n, the number of future events, through the end of the study, we apply Bagiella
and Heitjan’s formulas for Qj (t0, t) and Rj (t0, t). In our example, we do not assume a
censoring distribution since patients are followed through the electronic medical record,
and it is expected that there will be very little, if any, loss to follow-up. Thus, assuming a
constant administrative censoring time of 30 days, the formula for the number of expected
events in already enrolled patients in treatment group j is
Qj (t0, t) =
Nj(t0)∑
i=1
Yi (t0)
Fj (30)− Fj (t0 − eji)
[1− Fj (t0 − eji)] {t0 − eji < 30}
where Fj is the cumulative distribution function for the exponential distribution. The
rate of this distribution is a weighted average of observed data and the mean of the prior
distribution.
In studies with adaptive randomization, equal allocation to treatment groups is unlikely.
Therefore, we make a small notational change to the formula for estimating events in
patients to be enrolled, R (t0, t), to allow for changes in randomization proportions. Below,
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pi, the proportion of patients enrolled to the given treatment group, which may or may not
be constant throughout the study, replaces ν−1.
Rj (t0, t) = ρpi
∫ t−t0
0
{∫ t−t0−u
0
fj (s) (1−Gj (s)) ds
}
du
Assuming a 30 day constant censoring time, the expected number of events in patients
to be enrolled in treatment group j is
Rj (t0, t) = ρpi (t− t0)Fj (30)
4.3.2 Analytic vs. Numerical Event Estimate Numbers
To ensure that we have the best possible estimate of the number of events to occur by study
end, we compare two methods of estimating the number of future events obtained using
the formulas above and through completion of the study via simulation. At each interim
analysis, the formulas are used to estimate the total number of events at study end. We
compare these methods under a range of η values (0, 0.5, 1, 2) and treatment group
differences (0 to 30%) using the concept design suggested by Fiore et al. with 4 analyses
over 1,000 simulations of each scenario. Figure 4.1 demonstrates that the estimates from the
two methods are very similar regardless of the difference between the two treatment groups
and the calibration of the randomization probability. Generally, the analytic estimate is
within 10% of the simulated estimates (Table 4.1). Given the simplicity of the formulas
compared to simulation, we opt for event estimates via formula.
Table 4.1: Average % Difference (IQR) in Estimated Number of Events by Formula and
Simulation
η = ∆ = 0% ∆ = 20%
0 0.03 (0.01, 0.09) 0.03 (0.01, 0.09)
0.5 0.70 (0.24, 1.78) 2.17 (0.39, 6.13)
1 1.55 (0.51, 4.01) 5.63 (1.27, 14.32)
2 3.06 (0.92, 8.10) 1.55 (0.27, 5.84)
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Figure 4.1: Estimated Number of Events by Formula and Simulation
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4.3.3 Estimated and Observed Number of Events - Simulation Study
Given the performance of the formulas against simulations, we are interested in how esti-
mates of future event numbers from the formulas compare to the actual number of events
observed at the end of a study. The formulas are unable to account for the fact that a
study may stop early, so we remove the possibility of early stopping when making these
comparisons. We again consider a range of η values (0, 0.5, 1, 2) and treatment group
differences (0% and 20%) using Fiore et al.’s concept design with 4 analyses over 1,000
simulations of each scenario. For these simulations, we apply the normal approximation to
the posterior distribution and weight the prior distribution according described in Chapter
3.
4.3.4 Estimated and Observed Number of Events - Simulation Results
Figures 4.3 and 4.4 (pages 40 and 41) present event estimate numbers by formula against
the number of events observed at the end of a study by the analysis at which the estimates
were made. Additionally, Table 4.2 (page 39) provides the average percent difference
between observed event numbers and estimates.
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Across all scenarios estimates improve with time as more real study data is observed.
They also improve with larger treatment group differences. However, estimates early in
the study are subject to early random variation that may level over time as more data
is collected. This is particularly noticeable when there is little to no underlying treat-
ment difference. Further, for studies with adaptive treatment allocation (η = 0.5, 1, 2),
the formulas are not able to recover underlying treatment differences at early analyses.
This is because large differences heavily skew future treatment allocation. Event estimate
numbers are then based on the number of patients that are expected to enroll in each treat-
ment group, which is inaccurate when the observed treatment difference is much different
from underlying or final observed treatment differences. When early differences are large,
the formulas estimate to the end of the study based on false final treatment group sizes.
Estimates are generally within 10 to 20% of observed event numbers.
4.3.5 Estimation Performance Across Study Parameters - Simulation Study
We wish to further understand the range of the performance of the event estimate formulas.
To evaluate the performance under a variety of study designs we simulated 1,000 trials each
under a range of designs with exponential hospital length of stay. We considered sample
sizes of 50, 100 and 1000 with 2, 4 and 10 analyses. Randomization calibration ranged
from 0 to 2. True underlying treatment differences ranged from 0 to 30%. Type I error was
bounded at 0.05 for all designs prior distributions were assigned by the method described
in Chapter 3.
4.3.6 Estimation Performance Across Study Parameters - Simulation Results
Eight of these study designs are presented below under the null hypothesis (Figure 4.5, page
42) and under a 20% difference between treatment groups (Figure 4.6, page 43). Table
4.3 (page 44) provides the concordance coefficient by analysis for each of the eight study
designs plotted. Across all scenarios estimates improve as more data is accumulated and
studies with larger samples perform substantially better. Additionally, when randomization
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is highly skewed, estimates are generally better and improve more quickly over time than
those with equal allocation. This relationship is particularly pronounced in studies with
larger samples. In this case, when randomization is highly skewed, estimation is relatively
reliable after as little as 30% of the patients have been randomized. When there is an
underlying difference between the two treatment groups, studies with skewed randomization
initially perform worse than those without. However, after as few as one more batch of
patients have enrolled, studies with skewed randomization begin to estimate equivalently
to studies with equal randomization, and even begin to outperform.
While sample size, number of analyses and randomization calibration all seem to affect
accuracy of estimates, the number of observations the estimates are based upon are also
important. For example, studies with two analyses experience much more accuracy of
estimates when the sample size is 1,000 versus 50. That is, estimates are better when they
are based on 500 rather than 25 observations. The same is true for studies with more
analyses. Further, the improvement in accuracy is much more rapid in studies with larger
sample sizes. All of these relationships indicate that the absolute number of observations on
which estimates are based may play a more important role in accuracy than any individual
study parameter that we evaluated.
4.3.7 Estimation Performance Across Likelihoods - Simulation Study
While the exponential distribution is a convenient likelihood to assume when carrying
out time-to-event analyses, it may not always be the most accurate. In situations where
the event hazard is constant, the exponential likelihood may be a perfectly reasonable
assumption. However, depending on the condition studied, the observed hazard rate may
actually be increasing or decreasing with time. Thus, it is of interest to understand the
extent of the error in estimation introduced when we assume an incorrect likelihood. Given
the simplicity of the exponential distribution, we assume that the data follow a constant
hazard while varying the actual underlying hazard. We consider constant (shape = 1), early
(shape= 0.5), late (shape= 5) and increasing (shape = 2) hazards (Figure 4.2). Rates for
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these likelihoods were chosen to maintain the same median time to event, regardless of
hazard.
Figure 4.2: Weibull Hazards
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To compare the performance of the formulas for estimating event numbers under the
true likelihood to estimates when we assume an incorrect likelihood, we simulate 1,000
trials each under a range of study designs. We considered sample sizes of 50, 100 and 1000
with 2, 4 and 10 analyses. Randomization calibration ranged from 0 to 2. True underlying
treatment differences ranged from 0 to 30%. Type I error is bounded at 0.05 for all designs
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and prior distributions are assigned by the method in chapter 3.
4.3.8 Estimation Performance Across Likelihoods - Simulation Results
Simulation results comparing assumed and true hazards are presented in Figures 4.7 - 4.12
and Tables 4.4, 4.5, and 4.6 (pages 47, 50, and 53).
In general, for the range of hazards that we examined, assuming a constant hazard
when the underlying hazard is not constant has the potential to substantially affect the
performance of the event estimate formulas. When equal allocation is forced (η = 0),
the effect of the underlying hazard is most obvious. If the underlying hazard is early
(Figures 4.7 and 4.8, pages 45 and 46), the exponential event estimate formulas tend to
overestimate the actual number of events, regardless of the true underlying treatment
difference. Event estimates improve as more data is observed but estimates are always
high. Under increasing (Figures 4.9 and 4.10, pages 48 and 49) and late hazards (Figures
4.11 and 4.12, pages 51 and 52), the exponential event estimate formulas generally over
estimate the actual number of events until at least 75% of the data is observed over all
treatment differences we examined, at which point estimates become more reliable.
Estimates improve as more study data is observed and with larger underlying treatment
group differences. With non-zero treatment differences and adaptive randomization, less
data needs to be observed in order to make reliable estimates of future data because future
patients are more aggressively assigned to the better performing treatment. Across hazards,
estimates can be reliably made with as little as 25-50% when group differences are large.
While performance of the event estimate formulas is not as good under incorrect haz-
ard assumptions, performance consistently improves as more data is observed. In most
scenarios, after 50 to 75% of data is observed event estimate performance is approximately
the same under an incorrect hazard as it is under the correct hazard.
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4.3.9 Discussion
Given that the prior distribution is a tool to control for erroneous stopping when there are
large observed treatment differences early in the study, it is not entirely unexpected that
data from early analyses does not always provide accurate future event estimates. Early on,
the weight of the prior carries more influence than later in the study. For example, when
a study has 4 planned analyses, the sample provided by the prior distribution is 25% of
that provided by the data. Thus, at the first analysis, the data and the prior distribution
are contributing the same amount of information. Since the prior distribution assumes
no difference between the treatments, the posterior distribution used to provide effect
estimates to the event estimate formulas weights the mean of the predictive distribution
toward the null. At the second analysis, the data provides double the weight of the prior
distribution and the true underlying treatment difference can begin to outweigh the prior
distribution.
In these simulations, it is important to note that estimates are made after a predeter-
mined number of patients enroll. In many trials, interim analyses are carried out after a
predetermined number of events are observed, and power calculations are based on number
of events rather than sample size. In our example, the number of patients and the num-
ber of events are generally very similar at any given time due to the short time to event
relative to the administrative censoring time. If this were not the case, we would need to
account for the possible disparity between number of patients and number of events when
determining when and if we should carry out estimation of future events.
Across the study designs we evaluated there is a wide range of performance in estimation
of future events. Some scenarios present excellent estimation, while others show poor
estimation even after the study is nearly complete. However, of the scenarios presented
above, those with large sample sizes have reasonable estimation (concordance coefficient
greater than 0.8) after about 50% the sample has enrolled. Prior to that point, estimates
can be quite inaccurate, and it is not recommended to base decisions upon estimates made
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before this point. For smaller studies, particularly when study accrual is fast in relation to
the number of subjects planned to enroll, estimation is much more variable and estimation
should be carried out with caution.
It is not unexpected that we overestimate events under a true early hazard and under-
estimate under increasing and late hazards. With an early hazard, the application of a
constant hazard assumes that the same event rates that occurred early in the study will
continue to occur. Likewise, assumption of a constant hazard when the true hazard is
increasing or late will use the low event rate observed early in the study. In either case, the
event rates are changing as the study progresses and the event estimate formulas cannot
account for this when an exponential likelihood is assumed.
4.4 Simulation Results Figures and Tables
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Table 4.2: Average % Difference (IQR) in Estimated Number of Events and Observed
Events
η = k = ∆ = 0% ∆ = 10% ∆ = 20% ∆ = 30%
0
1
2
3
0.16
(0.08, 0.29)
0.12
(0.06, 0.22)
0.09
(0.04, 0.15)
0.14
(0.07, 0.26)
0.11
(0.05, 0.19)
0.08
(0.04, 0.14)
0.15
(0.07, 0.24)
0.11
(0.05, 0.18)
0.07
(0.03, 0.13)
0.13
(0.07, 0.23)
0.10
(0.05, 0.17)
0.07
(0.08, 0.28)
0.5
1
2
3
2.68
(0.90, 6.27)
1.05
(0.41, 2.33)
0.20
(0.08, 0.40)
10.82
(4.73, 19.05)
3.01
(1.39, 5.40)
0.38
(0.13, 0.75)
9.05
(0.48, 18.83)
0.03
(0.01, 2.00)
0.01
(0.005, 0.02)
0.17
(0.08, 0.28)
0.01
(0.003, 0.01)
0.005
(0.002, 0.01)
1
1
2
3
7.59
(2.63, 16.09)
2.69
(1.03, 5.48)
0.26
(0.10, 0.54)
9.87
(3.53, 19.46)
1.64
(0.40, 4.25)
0.26
(0.10, 0.57)
0.48
(0.18, 2.51)
0.02
(0.01, 0.10)
0.01
(0.004, 0.02)
0.15
(0.08, 0.26)
0.01
(0.003, 0.01)
0.005
(0.002, 0.008)
2
1
2
3
13.94
(4.93, 25.41)
3.50
(1.16, 8.36)
0.24
(0.10, 0.55)
2.04
(0.36, 12.48)
0.19
(0.03, 1.09)
0.04
(0.01, 0.18)
0.18
(0.09, 0.31)
0.01
(0.005, 0.02)
0.01
(0.004, 0.01)
0.15
(0.07, 0.25)
0.01
(0.003, 0.01)
0.005
(0.002, 0.008)
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Figure 4.3: Estimated Number of Events vs. Observed Events in Studies with Small
Treatment Difference
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Figure 4.4: Estimated Number of Events vs. Observed Events in Studies with Large
Treatment Difference
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Figure 4.5: Estimated Number of Events vs. Observed Events Under Varying Study De-
signs with Exponential Time-to-Event and No Treatment Difference
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Figure 4.6: Estimated Number of Events vs. Observed Events Under Varying Study De-
signs with Exponential Time-to-Event and 20% Treatment Difference
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Table 4.3: Concordance Coefficients for Observed vs. Estimated Number of Events Under
Varying Study Designs with Exponential Time-to-Event
k = ∆ = 0% ∆ = 20%
N = 50, η = 0
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.249
2
3
4
5
6
7
8
9
0.002
0.038
0.056
0.142
0.209
0.297
0.401
0.510
0.627
0.246
2
3
4
5
6
7
8
9
0.006
0.039
0.106
0.216
0.289
0.373
0.497
0.594
0.698
N = 50, η = 2
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.826
2
3
4
5
6
7
8
9
0.080
0.147
0.304
0.484
0.689
0.819
0.905
0.947
0.971
0.842
2
3
4
5
6
7
8
9
0.011
0.186
0.392
0.593
0.723
0.847
0.919
0.959
0.979
N = 1000, η = 0
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.540
2
3
4
5
6
7
8
9
0.058
0.179
0.355
0.451
0.536
0.629
0.723
0.803
0.878
0.520
2
3
4
5
6
7
8
9
0.015
0.157
0.281
0.449
0.562
0.673
0.736
0.809
0.885
N = 1000, η = 2
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.995
2
3
4
5
6
7
8
9
0.230
0.531
0.696
0.824
0.904
0.956
0.983
0.996
1.000
0.995
2
3
4
5
6
7
8
9
0.165
0.583
0.801
0.912
0.965
0.986
0.996
0.999
1.000
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Figure 4.7: Estimated Number of Events vs. Observed Events Under Varying Study De-
signs with Early Hazard and No Treatment Difference
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Figure 4.8: Estimated Number of Events vs. Observed Events Under Varying Study De-
signs with Early Hazard and 20% Treatment Difference
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Table 4.4: Concordance Coefficients for Observed vs. Estimated Number of Events Under
Varying Study Designs with Early Hazard
k = ∆ = 0% ∆ = 20%
N = 50, η = 0
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.020
2
3
4
5
6
7
8
9
0.004
0.009
0.014
0.016
0.024
0.031
0.034
0.044
0.054
0.029
2
3
4
5
6
7
8
9
0.001
0.007
0.010
0.017
0.022
0.030
0.038
0.053
0.063
N = 50, η = 2
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.353
2
3
4
5
6
7
8
9
0.020
0.124
0.287
0.425
0.551
0.629
0.675
0.696
0.707
0.396
2
3
4
5
6
7
8
9
0.014
0.115
0.300
0.467
0.588
0.679
0.732
0.757
0.772
N = 1000, η = 0
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.039
2
3
4
5
6
7
8
9
0.001
0.005
0.011
0.021
0.035
0.058
0.095
0.166
0.313
0.046
2
3
4
5
6
7
8
9
0.002
0.007
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0.024
0.040
0.066
0.111
0.189
0.344
N = 1000, η = 2
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3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.868
2
3
4
5
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7
8
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0.093
0.403
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0.741
0.866
0.942
0.976
0.993
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0.891
2
3
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9
0.158
0.462
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0.796
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0.994
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Figure 4.9: Estimated Number of Events vs. Observed Events Under Varying Study De-
signs with Increasing Hazard and No Treatment Difference
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Figure 4.10: Estimated Number of Events vs. Observed Events Under Varying Study
Designs with Increasing Hazard and 20% Treatment Difference
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Table 4.5: Concordance Coefficients for Observed vs. Estimated Number of Events Under
Varying Study Designs with Increasing Hazard
k = ∆ = 0% ∆ = 20%
N = 50, η = 0
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Figure 4.11: Estimated Number of Events vs. Observed Events Under Varying Study
Designs with Late Hazard and No Treatment Difference
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Figure 4.12: Estimated Number of Events vs. Observed Events Under Varying Study
Designs with Late Hazard and 20% Treatment Difference
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Table 4.6: Concordance Coefficients for Observed vs. Estimated Number of Events Under
Varying Study Designs with Late Hazard
k = ∆ = 0% ∆ = 20%
N = 50, η = 0
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.060
2
3
4
5
6
7
8
9
0.001
0.045
0.117
0.190
0.222
0.271
0.392
0.563
0.725
0.143
2
3
4
5
6
7
8
9
0.003
0.048
0.093
0.200
0.255
0.339
0.493
0.674
0.828
N = 50, η = 2
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.274
2
3
4
5
6
7
8
9
-0.001
0.008
0.016
0.029
0.080
0.192
0.375
0.642
0.840
0.558
2
3
4
5
6
7
8
9
-0.006
0.037
0.050
0.167
0.270
0.421
0.626
0.847
0.948
N = 1000, η = 0
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.283
2
3
4
5
6
7
8
9
0.002
0.017
0.059
0.111
0.216
0.343
0.491
0.685
0.841
0.315
2
3
4
5
6
7
8
9
0.005
0.036
0.115
0.201
0.331
0.483
0.621
0.781
0.889
N = 1000, η = 2
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.981
2
3
4
5
6
7
8
9
0.096
0.142
0.240
0.381
0.619
0.790
0.917
0.963
0.996
0.996
2
3
4
5
6
7
8
9
0.052
0.130
0.471
0.798
0.945
0.978
0.989
0.994
0.997
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Chapter 5
Stochastic Curtailment in Point-of-Care Trials
5.1 Motivation
Prediction of the outcome of a study prior to study conclusion can be very helpful to a study
team. Being able to assess whether or not a study will be successful prior to completion
can save a great deal of time and money. Likewise, it can provide further evidence to
continue a study to completion when interim results are not convincing. In the case of
frequentist clinical trials, this is achieved by study monitoring using conditional power,
or stochastic curtailment. This is different from studies with simple curtailment in which
the study terminates only when the result is known (i.e. when the test statistic exceeds a
pre-specified threshold). With stochastic curtailment, however, a study may end when we
know the result with high probability.
In POC trials, we can achieve the same monitoring through an analogous Bayesian tool
referred to as predictive power. If the probability of rejecting the null hypothesis at the end
of the study is very small, it may make financial sense to end a study early, thus saving the
resources that would have been otherwise expended. Conversely, if the probability of study
success is quite high, it is advantageous to complete the study in order to draw the scientific
conclusions the study was designed to evaluate. However, the value of the predicted power
of success of a study is dependent on whether those probabilities are reliable with respect
to actual conclusions at study end.
With the use of the normal distribution, predicted probabilities of any range of events
(e.g. study success) are relatively straightforward to calculate. In this chapter, we propose
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the use of a normal posterior distribution, with a transformation and approximation when
necessary, to achieve a normal distribution for prediction of future data. We use predicted
probabilities to draw conclusions about decisions at study end prior to study completion.
To evaluate the accuracy of these probabilities, predictive conclusions are compared to
conclusions based on posterior probabilities at the end of the study. Estimation of future
data to be used in prediction follows the method of Chapter 4. We consider the impact
of study design parameters on performance of prediction, as well as the ramifications of
incorrectly assuming the parameter likelihood is known.
5.2 Methods
5.2.1 The Predictive Distribution
In order to carry out prediction we need three pieces of information: 1) the likelihood of
the study parameter of interest, 2) the prior distribution for that study parameter, and
3) the distribution of data to be observed in the future. The first two pieces have been
discussed in prior chapters of this dissertation. However, we have yet to address 3), also
known as the predictive distribution.
In the Bayesian approach to stochastic curtailment, study results are predicted with the
posterior distribution in conjunction with a predictive distribution. Conclusions concerning
accepting or rejecting the null hypothesis are based on the posterior distribution that
incorporates observed data at the interim analysis, the prior distribution, and estimates of
data to be observed between the interim analysis and the end of the study. The distribution
of data yet to be observed is assumed to follow the same distribution as presently observed
data, with additional variability due to the estimation.
5.2.2 Prediction Under the Normal Distribution
The normal distribution presents a particularly convenient case for prediction because the
predictive distribution is also normal. Under a normal likelihood, the posterior distribution
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for analysis at the end of the study, after enrolling all subjects, (m+ n), is
θ|Tm+n ∼ N
(
(m+ n) tm+n + n0µ
m+ n+ n0
,
σ2
m+ n+ n0
)
where tm is the study parameter estimated with data through subject m, tn is the study
parameter estimated with future subjects n, and tm+n =
mtm+ntn
m+n is the study parameter
estimated with observed data through patient m and n future subjects. This is the distri-
bution that will be used for analysis at the end of the study. Before study completion, n
and tn are unobserved. To estimate probabilities at study end prior to study completion,
estimates of n and tn are needed. We can estimate n from the method described in Chap-
ter 4. Future data is assumed to follow the distribution of data already observed. Thus,
the conditional mean of Tn is the posterior mean of θ|Tm. Estimating future events add
additional variability to the distribution used for prediction, so the variance of Tn is the
posterior variance of θ|Tm plus the additional variability added by estimating future data.
The normal predictive distribution of Tn is
Tn|Tm ∼ N
(
mtm + n0µ
m+ n0
,
σ2
m+ n0
+
σ2
n
)
5.2.3 Choice of the Prior Distribution
Another important consideration when carrying out prediction is the choice of prior distri-
bution used for analysis. For the interim and final analyses in a group sequential design,
the choice of prior described in Chapter 3 is suitable for assuring bounded type I error.
However, in prediction, it is useful to consider multiple scenarios, namely, enthusiastic and
skeptical prior distributions.
If we are interested in showing superiority of treatment A over treatment B, then when
we attempt to conclude study results based upon estimated future data, we need to be
sure that the evidence is highly convincing. That is, even parties that are skeptical about
superiority of A over B should be convinced that the null hypothesis will be rejected at
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the end of the study and superiority will be concluded. In this case we use a skeptical
prior for prediction. Likewise, if we believe that it is highly unlikely that we will be able
to draw superiority conclusions about our hypotheses at the end of the study, then we
will need to convince even the most optimistic investigators that continuing the trial to
draw conclusions about the hypotheses is futile. In this scenario we use an enthusiastic, or
optimistic prior, for prediction.
A skeptical prior distribution is centered on a mean that represents the null value of
interest, for example, a difference of zero between treatment groups. The variance of this
distribution may be chosen such that the probability of the observed treatment difference
exceeding the specified alternative value is small (e.g. 5% or less). Similarly, an enthusiastic
prior distribution is centered on the treatment effect of interest with variance specified such
that the probability of an observed treatment different less than the null value is small. In
order to draw conclusions about the outcome of the study prior to study completion, we
need to consider all available evidence and a number of prior expectations.
5.3 Motivating Problem
5.3.1 Exact and Approximate Models
The inverse gamma posterior distribution for the POC insulin study is
λ|T, δ ∼ IG
(
α+
∑
δi, β + log (2)
∑
ti
)
Assuming the occurrence of a future event, ω, and an event time of y for each future
patient (jointly called Z), the predictive distribution of future data under the exact model
is of the form
f (Z|T, δ) = log (2) Γ (α+
∑
δi + ω)
[β + log (2) (
∑
ti + y)]
α+
∑
δi+ω
which does not follow a known distribution.
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As discussed in Chapter 2, the normal posterior distribution for log (λ) is
log (λ) |T,∆ ∼ N
∑ δi × log
(
λˆ
)
+ n0µ∑
δi + n0
,
1∑
δi + n0

If we assume the occurrence of n future events estimated via methods discussed in
Chapter 4, the predictive distribution also follows a normal distribution
Z|T,∆ ∼ N
∑ δi × log
(
λˆ
)
+ n0µ∑
δi + n0
,
1∑
δi + n0
+
1
n

5.3.2 Comparing Exact and Approximate Models - Simulation Study
We compared predictive probabilities under the exponential model and normal approxi-
mation to evaluate discrepancies between the two methods. Simulating the probabilities is
a two step process. First, samples are drawn from the predictive distribution at the given
analysis. Then, each of these samples is used to calculate a posterior probability of success
using the combination of observed and estimated study data as though it were the full
study data.
We examined 2,100 scenarios under a null and 20% difference in treatment groups.
The shape parameter of the inverse gamma prior (i.e. the weight of the prior distribution)
varied from 2.001 to 100, η ranged from 0 to 2, and the rejection bound b ranged from 0.95
to 0.999. We considered studies with sample sizes from 1,000 to 5,000 with 2, 3, 4, 5, and
10 analyses. Enrollment followed a Poisson process with a rate of 5 enrollees per day. We
carried out 1,000 simulations of each scenario with 100 predictive probabilities estimated
at each interim analysis. Prediction for each simulation was carried out under the exact
predictive distribution and under the approximate normal predictive distribution at each
interim analysis. Prediction was not carried out at the final analysis since this would
produce the same result as the final posterior probability for the study.
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5.3.3 Comparing Exact and Approximate Models - Simulation Results
We noted no substantial differences between the two methods in predictive probabilities
(Figure 5.1, page 64). The concordance of the two methods was not uniformly affected
by size difference in treatment groups, number of analyses, total number of participants,
analytic threshold, or prior weight. When there was a true underlying difference in the
treatment groups (right panel of Figure 5.1), the normal approximation can modestly
underestimate predictive probabilities in studies with adaptive randomization (η = 0.5, 1,
and 2).
We evaluated the methods controlling for the amount of data observed at the time
of prediction (Figure 5.2, page 65). Generally, there was more variability between the
two methods of prediction with less observed data. However, the the error between the
prediction methods was quite low regardless of the amount of data observed. Additionally,
under the assumption of an existing difference between the treatment groups the predictive
probability of a treatment difference shifts closer to 1 as the study progresses and more
data is observed. Thus, when the exact and approximate models are provided the same
information, predicted probabilities from the two methods are nearly indistinguishable.
5.3.4 Prediction Performance Across Study Parameters - Simulation Study
Given that prediction under the exact model and normal approximation perform equiva-
lently, we are interested in knowing whether prediction under the normal approximation is
a reliable tool with respect to actual study conclusions.
To evaluate the prediction performance under a variety of study designs we simulated
1,000 trials with 100 predictive probabilities estimated at each interim analysis. We con-
sidered sample sizes of 50, 100, 500, and 1000 with 2, 4 and 10 analyses. Randomization
calibration ranged from 0 to 2. True underlying treatment differences ranged from 0 to
30%. Type I error was bounded at 0.05 for all designs and simulations allowed for early
stopping.
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Additionally, we considered both a skeptical normal prior distribution for superiority
conclusions centered at no treatment difference and an enthusiastic normal prior distribu-
tion for study failure conclusions centered at a 10% treatment difference. A difference of
10% between treatments was chosen for the enthusiastic prior as the expectation in POC
trials is to achieve a treatment difference of no more than 10 - 15%. [6]
We calculated the posterior probability of superiority at study end as well as the pre-
dicted probability of superiority at each interim analysis. When considering study success,
a skeptical prior was used for both posterior and predicted probabilities. When considering
study failure, an enthusiastic prior was applied when calculating predicted probabilities.
Normal posterior probabilities were compared to a rejection threshold of 0.975 to deter-
mine if the null hypothesis was rejected at study end. Since early stopping was a possibility,
when studies ended early, the probability of superiority at that interim analysis was con-
sidered the final posterior probability for the study. At each interim analysis, predicted
probabilities of superiority were compared to the same rejection bound as the posterior
probabilities. The percentage of times these probabilities exceeded the rejection threshold
was recorded. The indicator of hypothesis rejection at study end was compared to the
percentage of times the study was predicted to reject across 1,000 simulations of the study
design to calculate a c statistic. For our purposes, the c statistic represents the probability
that predicting study outcome is better than chance.
5.3.5 Prediction Performance Across Study Parameters - Simulation Results
Twelve of the evaluated study designs are presented below (Figures 5.3 and 5.4, pages
66 and 67). Across all study designs and regardless of the study conclusion of interest, c
statistics improve as the study progresses and more data accrues. That is, as data accrues
prediction of study conclusions becomes more accurate. Prediction is also uniformly better
for larger sample sizes and c statistics are bounded much closer to 1. Accuracy of predicting
failure to reject the null hypothesis under an enthusiastic prior is somewhat more variable
than prediction of study success under the skeptical prior.
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5.3.6 Prediction Performance Across Likelihoods - Simulation Study
As with future event estimation in Chapter 4, we are interested in performance when as-
sumptions about the underlying likelihood are incorrect. The same hazards from Chapter
4 were considered (early, increasing, and late), and, as before, both enthusiastic and skep-
tical priors were applied where appropriate. To evaluate the performance of prediction
under different underlying hazards, we simulated trials with the three different likelihoods,
but analyzed the data as though we believed it followed a constant hazard, or exponential
likelihood. All simulation methods were the same as previously discussed.
5.3.7 Prediction Performance Across Likelihoods - Simulation Results
When the true underlying likelihood of the data follows a Weibull distribution with an early
hazard and a constant hazard is assumed, we tend to overestimate the number of events that
we will see at study end. This is reflected in the accuracy of prediction of study conclusions
(Figures 5.5 and 5.6, pages 68 and 69). The c statistics are generally lower than if the data
were actually exponentially distributed. Regardless of the conclusion of interest, sample
size, randomization calibration, and number of analyses, there is a consistent increase
in prediction accuracy as the study progresses. Larger studies have more potential for
better prediction accuracy than small studies. There is negligible difference in prediction
performance between concluding study success or study failure.
Similar to previously examined scenarios, when the true underlying likelihood has an
increasing hazard, prediction tends to improve as the study progresses (Figures 5.7 and
5.8, pages 70 and 71). This is particularly evident when study success is the outcome of
interest. Because we assume a constant hazard, the event rate is underestimated at each
interim analysis. However, as the study progresses, estimates of future data improve, thus
providing more accurate information to the prediction model. As such, prediction improves
and variability in predictive accuracy decreases.
When considering study failure in conjunction with an increasing hazard c statistics are
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generally quite high. The ramifications of assuming a constant hazard when the underlying
hazard is increasing are limited with respect to whether we will reject the null hypothesis
at study end. It is important to note that the final analysis of study data also assumes an
incorrect likelihood, so while conclusions from the completed study and prediction of the
completed study are concordant, the final study conclusion may not be accurate.
When the true underlying likelihood has a late hazard and study success is of interest
(Figures 5.9 and 5.10, pages 72 and 73), prediction performance is variable among study
designs. The effect of the late hazard with adaptive randomization makes the prediction
estimates somewhat volatile. We have the potential to estimate wildly incorrect treatment
differences depending on what we observe at a given interim analysis. This is more apparent
in studies with large samples because there is more room for a large magnitude of error in
future data estimates.
When considering study failure, patterns in prediction accuracy for small studies are
the same as when considering study success. However, early in large studies with many
analyses, an enthusiastic prior can force additional treatment difference into the analysis.
Since few events are observed early in the study when the hazard is late, the optimistic
prior applies undue weight to treatment differences that may not exist. Additionally, the
optimistic prior may begin to oppose the observed data as the study progresses, thus
causing additional variability in prediction accuracy.
5.3.8 Discussion
When assumptions about the underlying hazard are correct, the c statistic for prediction
typically begins to exceed 0.8 after 50-75% of the data have been observed, regardless of
study design and prior choice. For small studies, accurate prediction may require more
data to be observed. As such, stochastic curtailment in POC studies may not be a useful
tool when the number of subjects is small since it may not reliable until 80-90% of the data
have been observed. However, for large studies, knowing with some degree of certainty
whether or not a study will be successful has the potential to save a great deal of money
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and time.
If we incorrectly assume a constant hazard, when in fact the underlying likelihood
has an early hazard, we may still be able to rely on stochastic curtailment for accurate
conclusions about study end despite overestimates of future events. As with a correct
likelihood assumption, prediction in small studies may not be useful since the study must
be carried almost to completion to have reliable prediction. Studies with a large planned
sample size can still have good prediction accuracy after the study is only half-completed.
Studies with underlying late and increasing hazards experience much better prediction
performance in small studies than studies with early or constant hazard. This is likely
because the studies are too short to experience the spike in event rates that results from
these hazards. Thus, the fact that estimates of future event data are somewhat inaccurate
does not ultimately seem to affect whether predictive probabilities reflect conclusions at the
end of the study. Given that we are unlikely to have enough evidence at an early interim
analysis to stop the study for superiority, an enthusiastic look at the data concerning study
failure may be preferable for prediction at that point to ensure that we do not incorrectly
decide to stop the study early for futility. Likewise, as the study continues and evidence of
treatment differences accrues, we become more likely to reject the null hypothesis. At these
later analyses, a skeptical view for prediction is preferred to ensure we do not incorrectly
decide that the study will be successful.
Of note are scenarios in which the estimated c statistic is less than 0.5. This means that
using the predictive probability is actually worse at determining study conclusions than
chance. The cases in which c statistics are less than 0.5 fall into the following categories:
1) prediction at an early analysis, 2) incorrect assumption of underlying hazard, and 3)
the prior distribution does not accurately reflect the underlying treatment difference. For
example, the first analysis of 10 in a study with increasing hazard, 30% treatment difference
and a skeptical prior distribution produces a c statistic of 0.44. We are providing the
prediction model with multiple sources of incorrect information, thus resulting in poor
prediction of study conclusions.
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5.4 Simulation Results Figures
Figure 5.1: Predictive Probabilities under the Exact Model and Normal Approximation
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Figure 5.2: Predictive Probabilities under the Exact Model and Normal Approximation
Over Time
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Figure 5.3: Distribution of c Statistics for Concluding Study Success
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Figure 5.4: Distribution of c Statistics for Concluding Study Failure
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Figure 5.5: Distribution of c Statistics for Concluding Study Success Under Early Hazard
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Figure 5.6: Distribution of c Statistics for Concluding Study Failure Under Early Hazard
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Figure 5.7: Distribution of c Statistics for Concluding Study Success Under Increasing
Hazard
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Figure 5.8: Distribution of c Statistics for Concluding Study Failure Under Increasing
Hazard
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Figure 5.9: Distribution of c Statistics for Concluding Study Success Under Late Hazard
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Figure 5.10: Distribution of c Statistics for Concluding Study Failure Under Late Hazard
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Chapter 6
Conclusions and Future Work
In this dissertation, adaptive methodology for clinical trials was developed and evaluated
for point-of-care clinical trials with limited censoring. Use of a normal approximation was
proposed for trials in which the study parameter of interest does not follow a normal dis-
tribution. We developed a normal approximation for our motivating example and assessed
its accuracy with respect to frequentist type I and II errors. In our example, the normal
approximation performed exceptionally well.
After the choice to use a normal approximation to the likelihood had been made,
we applied a previously developed method for choosing an normal prior distribution for
analysis. We evaluated the performance of this approach in conjunction with a normal
approximation under both equal and adaptive randomization for our example POC study.
When equal allocation was forced, the choice of analytic prior distribution was the same
as previously published. However, the choice of prior changed depending on the severity
of adaptive allocation.
Having established a method for choosing an analytic prior for use in conjunction with
collected data, we used current data along with the prior to estimate the number of events
to be expected at the end of the study. A previously published method for event estimation
was modified to allow for unbalanced randomization and inclusion of prior information. We
applied this method to our motivating example to evaluate accuracy of estimates and the
effect of study design and incorrect assumptions on performance. For reasonably sized
studies in which we know the underlying distribution of the study parameter, this method
generally provides reliable estimates after about 50% of the expected data has been ob-
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served, regardless of sample size in the cases we considered.
With these future data estimates, we proceeded to make predictions about conclusions
at study end. We proposed using a normal approximation when possible to calculate pre-
dicted probabilities of study success, and used our motivating problem as an example of
how to carry out these calculations. We considered performance of the predicted probabil-
ities with respect to actual study conclusions considering prior distribution choice, study
design, and use of an incorrect likelihood for analysis. As with future event estimates,
prediction was often accurate after 50% or more of the data for a study had been observed
for studies of 50 subjects or more.
The limitations of the work presented in this dissertation provide opportunities for
continued, future research.
The proposed use of a normal approximation is only applied to one scenario with a
simple likelihood and a clear conjugate prior distribution. Additional likelihoods, and in
particular, those without a clear conjugate prior distribution are of interest for further
investigation. While the exponential likelihood is easy to work with, it is not always
realistic as it assumes a constant hazard. A normal approximation was applied throughout
this dissertation, even when the likelihood on which the approximation was based was not
the true underlying likelihood. When the correct likelihood was assumed in our example,
the approximation worked well across the methods discussed here. Of interest is how
the normal approximation performs when it is based on a likelihood with a non-constant
hazard and it matches the true underlying likelihood. Understanding of the performance
of a normal approximation under non-constant hazards would be useful for a wide variety
of diseases.
Additionally, our motivating example incorporates only a constant administrative cen-
soring. Point-of-care studies are unusual in that subjects can be followed through the
medical record, and therefore we expect very little loss of follow-up. However, for tradi-
tional randomized clinical trials or non-POC adaptive clinical trials, censoring is a concern.
Inclusion of a censoring distribution would expand the usefulness of this methodology. Fur-
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thermore, the effect of assuming the incorrect censoring distribution is of interest. In par-
ticular, addition of censoring would greatly affect the estimation of the number of future
events, and as a result, prediction of study conclusions.
Though not explored here, other approaches to randomization adaptation are available.
For example, Thall and Wathen propose a function for η that updates over the course of
the trial. [10] The effect of this type of adaptation is of interest for further study and could
potentially provide additional control for early stopping. In some scenarios throughout
this dissertation, adaptive randomization can put our proposed methods at a disadvantage.
However, all adaptations we considered were constant. Thall and Wathen’s non-constant
adaptive technique may attenuate the effect of randomization on methods discussed in this
dissertation.
When carrying out prediction of study conclusions before study end, we used c statistics
to evaluate how well our predicted conclusions matched actual conclusions at study end.
These statistics depend on a threshold to which we compare probabilities of superiority.
In practice, knowing the optimal threshold(s) could be useful to ensure that our predicted
conclusions are concordant with final study conclusions. This would be particularly useful
when the c statistic is not large.
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